Ariel Teper
Insmed (United States)(US)Insmed (United Kingdom)(GB)
Publications by Year
Research Areas
Asthma and respiratory diseases, IL-33, ST2, and ILC Pathways, Cystic Fibrosis Research Advances, Allergic Rhinitis and Sensitization, Dermatology and Skin Diseases
Most-Cited Works
- → Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma(2018)1,869 cited
- → Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma(2018)1,122 cited
- → Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial(2016)869 cited
- → Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial(2015)564 cited
- → Conjunctivitis in dupilumab clinical trials(2019)411 cited
- → Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma(2019)198 cited